221 filings
Page 3 of 12
8-K
gewoh31afau
9 May 23
Termination of a Material Definitive Agreement
4:15pm
8-K
hskcs8 n27wq
1 May 23
Entry into a Material Definitive Agreement
6:15am
8-K
zvpdzbzj
21 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
cy4jopps7z05d8
31 Mar 23
Unregistered Sales of Equity Securities
4:53pm
NT 10-K
ojypray9ofid5chag
31 Mar 23
Notice of late annual filing
4:15pm
8-K
ybm6ltwd9om8rfhq9ro
28 Mar 23
Termination of a Material Definitive Agreement
5:49pm
8-K
938efpd1g
22 Mar 23
Departure of Directors or Certain Officers
4:05pm
424B5
m69g0s298034m
16 Mar 23
Prospectus supplement for primary offering
6:05am
8-K
n09c06qa
15 Mar 23
Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock
9:12am
8-K
cy9o6g1
13 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
D
skd0o16m
20 Dec 22
$4.85 mm in equity, sold $4.85 mm, 1 investor
6:15am
424B3
h2v65ye5b5
15 Dec 22
Prospectus supplement
4:33pm
EFFECT
j50pe9j vogv
15 Dec 22
Notice of effectiveness
12:15am
8-K
aea2ry
12 Dec 22
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
9:05am
CORRESP
gagcs
12 Dec 22
Correspondence with SEC
12:00am
UPLOAD
9z6mbkr20onkejf
12 Dec 22
Letter from SEC
12:00am
S-8
mpghzq11n7 y6ug4di3e
5 Dec 22
Registration of securities for employees
8:23pm
8-K
kukc1102fy41z8kvfc
21 Nov 22
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results
8:34pm